申请人:Euro-Celtique S.A.
公开号:US20030055088A1
公开(公告)日:2003-03-20
This invention relates aryl substituted pyridines of Formula I:
1
or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein Ar and R
1
-R
4
are set in the specification. The invention is also directed to the use of compounds of Formula I for the treatment of neuronal damage following global and focal ischemia, for the treatment or prevention of neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS), and for the treatment, prevention or amelioration of both acute or chronic pain, as antitinnitus agents, as anticonvulsants, and as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy.
本发明涉及公式I的芳基取代吡啶化合物:1或其药学上可接受的盐、前药或溶剂化物,其中Ar和R1-R4在规范中设置。本发明还涉及使用公式I的化合物治疗全局和局部缺血后的神经损伤,治疗或预防神经退行性疾病,如肌萎缩性侧索硬化症(ALS),以及治疗、预防或缓解急性或慢性疼痛,作为抗耳鸣剂,抗癫痫药物和抗躁狂抑郁药物,局部麻醉剂,抗心律失常药物以及治疗或预防糖尿病神经病变的用途。